Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00875017 · ClinicalTrials.gov registry record · Phase 1
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
A Phase 1 study of Kidney Failure, Chronic, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00875017 is a Phase 1 study of Kidney Failure, Chronic that has completed, run by Shire. The registered enrollment target is 31 participants, below the 331-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00875017, a Phase 1 study of Kidney Failure, Chronic, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).
Conditions Studied
Interventions
- DRUG Sevelamer
- DRUG Lanthanum Carbonate
Study Locations (1)
California
- West Coast Clinical Trials - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-04-20 |
| Est. Completion | 2009-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00875017
The ClinicalTrials.gov registry entry for NCT00875017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (91% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Sevelamer is the first listed.
NCT00875017 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00875017 about?
NCT00875017 is a clinical study titled "Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers". The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).
What is the current status of trial NCT00875017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-04-20. Estimated completion is 2009-06-16.
What conditions does trial NCT00875017 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic.
What interventions are being tested in trial NCT00875017?
The interventions under investigation include: Sevelamer (DRUG), Lanthanum Carbonate (DRUG).
Who is sponsoring clinical trial NCT00875017?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00875017 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Empagliflozin in ESKD - A Feasibility Study
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
COMPLETED · Phase 1
-
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
COMPLETED · Phase 1
-
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.